#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | NCI Cancer Stats @NCICancerStats Rates for new lung and bronchus #cancer cases have been falling ~2.1% each year over the last 10 years. Get more stats on this cancer here: https://t.co/r2KcvFYGBy #LCSM https://t.co/vojbJcnpC3 |
 | Bob Steele @steele_bob RT @jillfeldman4: @BrendonStilesMD it is seriously entertaining to see the tweeting back and forth with you and rad oncs #lcsm |
 | Janet Freeman-Daily @JFreemanDaily Welcome to #LCSM Chat! We’re back from summer hiatus with tonight’s topic “Highlights of #WCLC2018.” Read more here: https://t.co/holHceT8fU |
 | Nathan A. Pennell MD, PhD, FASCO @n8pennell Nate Pennell, med onc from Cleveland here! #lcsm |
 | LungCancerFoundation @TheALCF Come out on #Sunday #October 7 in beautiful #Mukilteo #Washington to Bust Your Lungs at the #Lungbuster #5k / #10k and help fund research for #ROS1 Positive #LungCancer treatments --> https://t.co/IxAMo0Tst8 #LCSM #beatlungcancer #lungcancerresearch #5k #hope https://t.co/gj5nPsCEWN |
 | Brendon Stiles @BrendonStilesMD @JFreemanDaily @merelhennink Can you believe it slipped away! Remembered it two days later and was looking for a time to post! #lcsm |
 | Bonnie J. Addario @bonniejaddario Come out on #Sunday #October 7 in beautiful #Mukilteo #Washington to Bust Your Lungs at the #Lungbuster #5k / #10k and help fund research for #ROS1 Positive #LungCancer treatments --> https://t.co/S5V4hlOrJJ #LCSM #beatlungcancer #lungcancerresearch #5k #hope https://t.co/DgDfoCLQUp |
 | Faces of Lung Cancer @LungCancerFaces @n8pennell Hey, Nate! #lcsm |
| Brendon Stiles @BrendonStilesMD @n8pennell The legend. #lcsm |
| Janet Freeman-Daily @JFreemanDaily I’m your moderator Janet Freeman-Daily: writer (https://t.co/OBCc88h7Jg), science geek, stage IV #lungcancer patient/activist #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: I’m your moderator Janet Freeman-Daily: I’m your moderator Janet Freeman-Daily: writer (https://t.co/OBCc88h7Jg), science geek, stage IV #lungcancer patient/activist #lcsm |
 | #LCSM Chat @lcsmchat RT @JFreemanDaily: Welcome to #LCSM Chat! We’re back from summer hiatus with tonight’s topic “Highlights of #WCLC2018.” Read more here: Welcome to #LCSM Chat! We’re back from summer hiatus with tonight’s topic “Highlights of #WCLC2018.” Read more here: https://t.co/holHceT8fU |
| Janet Freeman-Daily @JFreemanDaily Our special guests tonight: the @IASLC Communications Team! Thanks for joining us. #lcsm |
| Janet Freeman-Daily @JFreemanDaily We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I’m your moderator Janet Freeman-Daily: I’m your moderator Janet Freeman-Daily: writer (https://t.co/OBCc88h7Jg), science geek, stage IV #lungcancer patient/activist #lcsm |
 | Joni Fowler, PharmD, BCPP @jfowlerpharmd Hi, everyone! 👋🏼 #lcsm |
 | Jill Feldman @jillfeldman4 HAPPENING NOW! #LCSM |
| Brendon Stiles @BrendonStilesMD @jillfeldman4 You feel kind of bad from them, right? I felt like I was way ahead of them tonight! Couldn't stop! #lcsm |
| Janet Freeman-Daily @JFreemanDaily If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSzfTD |
| Bob Steele @steele_bob RT @JFreemanDaily: Our special guests tonight: Our special guests tonight: the @IASLC Communications Team! Thanks for joining us. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell This discussion at tumor board makes it hard to get through the list. Get a room guys! #lcsm |
 | David LeDuc @Duke_of_Urbana RT @TheALCF: Come out on #Sunday #October 7 in beautiful #Mukilteo #Washington to Bust Your Lungs at the #Lungbuster #5k / #10k and help fund research for #ROS1 Positive #LungCancer treatments --> https://t.co/IxAMo0Tst8 #LCSM #beatlungcancer #lungcancerresearch #5k #hope https://t.co/gj5nPsCEWN |
 | IASLC @IASLC Hi this is Becky from the IASLC here. I’m filling in for our social media expert, Adam, so be patient with me here. So glad for tonight’s discussion. #LCSM #WCLC2018 |
| Faces of Lung Cancer @LungCancerFaces Deana Hendrickson in Los Angeles here. Excited to chat about #WCLC2018! #lcsm |
| Brendon Stiles @BrendonStilesMD @jillfeldman4 In all seriousness though---the dialogue and back and forth is incredible and how we all learn from each other to help patients. #lcsm |
| Janet Freeman-Daily @JFreemanDaily #LCSM Chat welcomes Timothy Craig Allen @TimAllenMDJD to our team of moderators! Looking forward to working with you, Tim. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Our special guests tonight: Our special guests tonight: the @IASLC Communications Team! Thanks for joining us. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| Faces of Lung Cancer @LungCancerFaces @jfowlerpharmd Hi Joni! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Please remember to use #lcsm in all your tweets so others participating in the chat can see them |
 | Deb Smith 🌻 @debsmithbeach @JackWestMD Yes, I'm very interested in that too! I've been on osi (1st 2 1/2 yrs on a trial @DanaFarber ) for 5 yrs this month. Glad there info coming on EGFR/T790 resistance. Gives me hope! #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: Hi this is Becky from the IASLC here. I’m filling in for our social media expert, Adam, so be patient with me here. So glad for tonight’s discussion. #LCSM #WCLC2018 |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily @TimAllenMDJD Everyone needs a world class pathologist. #lcsm |
| Jill Feldman @jillfeldman4 @BrendonStilesMD LOL, I would love for @DrewMoghanaki to join a #lcsm twitter chat one time! |
| Bob Steele @steele_bob Bob here in lovely Greensboro, NC. Really glad to see the Lung Cancer Social Media bi-weekly Twitter #lcsm |
 | Betsy @MAmaskwearer Hello people! #LCSM |
| Jill Feldman @jillfeldman4 @jfowlerpharmd Hi Joni! #lcsm |
| Brendon Stiles @BrendonStilesMD @n8pennell What is more exciting than Lung cancer oncology these days???? #lcsm |
 | Denise Cutlip @dennycee #lcsm MI in the house and 7 days away from my 8 yr st 4 cancerversary. |
| Faces of Lung Cancer @LungCancerFaces @steele_bob Hi Bob! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @wildwestannie Hello Gorgeous #lcsm |
| Faces of Lung Cancer @LungCancerFaces @dennycee Hey you #lcsm |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: #LCSM Chat welcomes Timothy Craig Allen @TimAllenMDJD to our team of moderators! Looking forward to working with you, Tim. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @JFreemanDaily @TimAllenMDJD Everyone needs a world class pathologist. #lcsm |
| Bob Steele @steele_bob RT @dennycee: #lcsm MI in the house and 7 days away from my 8 yr st 4 cancerversary. |
| Janet Freeman-Daily @JFreemanDaily If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
 | Lecia Sequist, MD, MPH @LeciaSequist @BrendonStilesMD @n8pennell Answer: nothing!!! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #LCSM Chat welcomes Timothy Craig Allen @TimAllenMDJD to our team of moderators! Looking forward to working with you, Tim. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @LeciaSequist Whoa! You're here. Yay @BrendonStilesMD @n8pennell #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: #LCSM Chat welcomes Timothy Craig Allen @TimAllenMDJD to our team of moderators! Looking forward to working with you, Tim. #lcsm |
| Janet Freeman-Daily @JFreemanDaily .@TimAllenMDJD We've already welcomed you into the #LCSM Chat moderator team! See what happens when you're late? :) |
 | Sara Whitlock @sjwhitlock Sara here. Watching soccer so excuse typos! #LCSM |
| Faces of Lung Cancer @LungCancerFaces @tilting Welcome! You're among friends here. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Join in! Great folks here. #lcsm |
| Brendon Stiles @BrendonStilesMD @LeciaSequist @n8pennell That is what I am talking about! Even opened a recent editorial stating that “oncologists are the stars of lung cancer treatment these days”. Really hurt me to admit. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @TimAllenMDJD Hi Tim! We're so glad you've agreed to join our core team. #lcsm |
| Brendon Stiles @BrendonStilesMD @sjwhitlock Feel free to send more pics. #lcsm |
 | LungCancer.net @LungCancer_HU Margot here from https://t.co/4ebZcoIISH #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Lol. Happy to be here. #PatientsFirst #lcsm |
| Faces of Lung Cancer @LungCancerFaces @sjwhitlock Welcome! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @LungCancer_HU Hey Margot #lcsm |
 | Vamsi Velcheti, MD @VamsiVelcheti Vamsi Velcheti @nyuschoolofmed NYC here #LCSM |
| Brendon Stiles @BrendonStilesMD @LungCancerFaces @LeciaSequist @n8pennell Another legend. They are stacking up. #lcsm |
| Deb Smith 🌻 @debsmithbeach Deb here, from the lovely NH Seacoast. #lcsm |
| Brendon Stiles @BrendonStilesMD @VamsiVelcheti @nyuschoolofmed Still hurts me seeing that NYU tag. Hope all is well. #lcsm |
| Betsy @MAmaskwearer @LungCancerFaces I mean, aww, #lcsm 😊 |
 | It's me! @JohnLPender . #lcsm |
| Faces of Lung Cancer @LungCancerFaces @debsmithbeach Hi Deb! Long time no chat #lcsm |
| Faces of Lung Cancer @LungCancerFaces @JohnLPender Hey John #lcsm |
 | Tim Kruser @TimothyKruserMD @BrendonStilesMD @jillfeldman4 Rad Onc checking in. Don't feel bad for us ;) #lcsm |
 | colleen ziegler @ZieglerColleen Hello all, Colleen from Rochester joining in #lcsm |
| Janet Freeman-Daily @JFreemanDaily #WCLC2018 is the World Conference on Lung Cancer. This year it was in Toronto Sep 23-26 and covered wide range of #lungcancer topics. #lcsm |
| Janet Freeman-Daily @JFreemanDaily This #LCSM Chat will be different. Starting at about 5:10 PDT, we will share a new tweet on a top #WCLC2018 presentation approx every 5 min |
| Faces of Lung Cancer @LungCancerFaces @TimothyKruserMD Welcome Doc! @BrendonStilesMD @jillfeldman4 #lcsm |
 | Daniel Cadigan @LungRoadAhead #lcsm Dan here. Good to join in |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: #WCLC2018 is the World Conference on Lung Cancer. This year it was in Toronto Sep 23-26 and covered wide range of #lungcancer topics. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Feel free to share #WCLC2018 take-away slides or pics that convey the feel of the conference and/or important info #lcsm |
| Brendon Stiles @BrendonStilesMD @TimothyKruserMD @jillfeldman4 In the house. Hoping to meet you soon Tim! #lcsm |
 | Peggy Dennis @peggyddennis #LCSM Peggy from Denver joining |
| Faces of Lung Cancer @LungCancerFaces @ZieglerColleen Hey Colleen! #lcsm |
| Janet Freeman-Daily @JFreemanDaily We won’t have a lot of time for discussion, but we’ll try to answers all questions during or after the chat. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @LungRoadAhead Hi Dan! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: This #LCSM Chat will be different. Starting at about 5:10 PDT, we will share a new tweet on a top #WCLC2018 presentation approx every 5 min |
| Faces of Lung Cancer @LungCancerFaces @peggyddennis Welcome Peggy! #lcsm |
| IASLC @IASLC #LCSM Chat Tweet 1: At #WCLC2018, we were lucky to catch up with @rdoebele, who updated us on the research he presented at the conference. #AdvancedNSCLC https://t.co/yx4n1JKCSh |
| Lecia Sequist, MD, MPH @LeciaSequist @bensolomon1 @chrisdraft @TommyJohn00 @Lungfoundation @teamdraft This is a great pic of 3 amazing lung cancer giants!! And all with the same hairdo too!! Love these guys!! #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: This #LCSM Chat will be different. Starting at about 5:10 PDT, we will share a new tweet on a top #WCLC2018 presentation approx every 5 min |
| Janet Freeman-Daily @JFreemanDaily Glad to see familiar Twitter handles as well as new participants tonight! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Feel free to share #WCLC2018 take-away slides or pics that convey the feel of the conference and/or important info #lcsm |
| Bob Steele @steele_bob Looks like lots of great reading ahead from the IASLC conference! Awesome! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We won’t have a lot of time for discussion, but we’ll try to answers all questions during or after the chat. #lcsm |
| Denise Cutlip @dennycee @tilting welcome onthemark, I’m aka Denzie. Glad you’re here. #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 1: #LCSM Chat Tweet 1: At #WCLC2018, we were lucky to catch up with @rdoebele, who updated us on the research he presented at the conference. #AdvancedNSCLC https://t.co/yx4n1JKCSh |
 | Anita Figueras @scifiknitter Anita from northern NY & the EGFR Resisters joining the chat. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @scifiknitter Yay! Anita's here #lcsm |
| Brendon Stiles @BrendonStilesMD For me best part of #wclc2018 is always the shared experience with colleagues and patients. Incredible dialogue. #lcsm https://t.co/RreCqHSXXK |
 | Lung Cancer Sux @LungCancerSux @BrendonStilesMD @sjwhitlock #lcsm dx 9/2010 https://t.co/talHlX75C8 |
| Janet Freeman-Daily @JFreemanDaily Dr. Doebele had a LOT of presentations, including the data on entrectinib for ROS1+ NSCLC. Hopeful we'll have new tx for @ros1cancer. #lcsm |
 | Charu Aggarwal, MD, MPH @CharuAggarwalMD RT @BrendonStilesMD: Get ready for the host with the most - @JFreemanDaily as we recap #WCLC2018 #lcsm https://t.co/Y8d3xBQ6Tw |
| Faces of Lung Cancer @LungCancerFaces @tilting @dennycee This will be a very atypical chat, so don't judge by this one... #lcsm |
| Denise Cutlip @dennycee Welcome Margot! Happy you’re here. RT @LungCancer_HU: Margot here from https://t.co/FpvuVTnzsa #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: For me best part of #wclc2018 is always the shared experience with colleagues and patients. Incredible dialogue. #lcsm https://t.co/RreCqHSXXK |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 1: #LCSM Chat Tweet 1: At #WCLC2018, we were lucky to catch up with @rdoebele, who updated us on the research he presented at the conference. #AdvancedNSCLC https://t.co/yx4n1JKCSh |
| Faces of Lung Cancer @LungCancerFaces @LungCancerSux Love this @BrendonStilesMD @sjwhitlock #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Dr. Doebele had a LOT of presentations, including the data on entrectinib for ROS1+ NSCLC. Hopeful we'll have new tx for @ros1cancer. #lcsm |
| Brendon Stiles @BrendonStilesMD The patient advocacy/focused mutation groups are doing incredible work. @EGFRResisters @ALKLungCancer @ros1cancer #lcsm |
| Jill Feldman @jillfeldman4 One of my favorite pics from the conference! #LCSM https://t.co/7FCvD5siMm |
| Bob Steele @steele_bob RT @BrendonStilesMD: The patient advocacy/focused mutation groups are doing incredible work. @EGFRResisters @ALKLungCancer @ros1cancer #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @jillfeldman4: One of my favorite pics from the conference! #LCSM https://t.co/7FCvD5siMm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: The patient advocacy/focused mutation groups are doing incredible work. @EGFRResisters @ALKLungCancer @ros1cancer #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: One of my favorite pics from the conference! #LCSM https://t.co/7FCvD5siMm |
| Jill Feldman @jillfeldman4 RT @BrendonStilesMD: The patient advocacy/focused mutation groups are doing incredible work. @EGFRResisters @ALKLungCancer @ros1cancer #lcsm |
| Janet Freeman-Daily @JFreemanDaily .@BrendonStilesMD Thanks! Excited that our presentation on oncogene-driven patient groups was mentioned in @WCLC2018 closing plenary. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Dr. Doebele had a LOT of presentations, including the data on entrectinib for ROS1+ NSCLC. Hopeful we'll have new tx for @ros1cancer. #lcsm |
| IASLC @IASLC #LCSM Chat Tweet 2: “Developments in the last ten years have really galvanized the lung cancer community.” - Advocate @jillfeldman4 talks in the #WCLC2018 press conference about how recent advances are providing extraordinary new hope to patients and their families. #Advocacy https://t.co/b2UhGYV8ed |
| Brendon Stiles @BrendonStilesMD Amazing thing about #wclc2018 was the progress on multiple fronts: screening, stage III, small cell, immunotherapy, targeted therapy. Incredible time to be involved in lung cancer. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: For me best part of #wclc2018 is always the shared experience with colleagues and patients. Incredible dialogue. #lcsm https://t.co/RreCqHSXXK |
| Denise Cutlip @dennycee @tilting @LungCancerFaces @dennycee onthemark is a sponge for accurate info. He’ll keep up. #lcsm |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 2: #LCSM Chat Tweet 2: “Developments in the last ten years have really galvanized the lung cancer community.” - Advocate @jillfeldman4 talks in the #WCLC2018 press conference about how recent advances are providing extraordinary new hope to patients and their families. #Advocacy https://t.co/b2UhGYV8ed |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: .@BrendonStilesMD Thanks! Excited that our presentation on oncogene-driven patient groups was mentioned in @WCLC2018 closing plenary. #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 2: #LCSM Chat Tweet 2: “Developments in the last ten years have really galvanized the lung cancer community.” - Advocate @jillfeldman4 talks in the #WCLC2018 press conference about how recent advances are providing extraordinary new hope to patients and their families. #Advocacy https://t.co/b2UhGYV8ed |
 | Vivek Subbiah, MD @VivekSubbiah RT @jillfeldman4: One of my favorite pics from the conference! #LCSM https://t.co/7FCvD5siMm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Amazing thing about #wclc2018 was the progress on multiple fronts: Amazing thing about #wclc2018 was the progress on multiple fronts: screening, stage III, small cell, immunotherapy, targeted therapy. Incredible time to be involved in lung cancer. #lcsm |
| Jill Feldman @jillfeldman4 RT @IASLC: #LCSM Chat Tweet 2: #LCSM Chat Tweet 2: “Developments in the last ten years have really galvanized the lung cancer community.” - Advocate @jillfeldman4 talks in the #WCLC2018 press conference about how recent advances are providing extraordinary new hope to patients and their families. #Advocacy https://t.co/b2UhGYV8ed |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: .@BrendonStilesMD Thanks! Excited that our presentation on oncogene-driven patient groups was mentioned in @WCLC2018 closing plenary. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @IASLC: #LCSM Chat Tweet 2: #LCSM Chat Tweet 2: “Developments in the last ten years have really galvanized the lung cancer community.” - Advocate @jillfeldman4 talks in the #WCLC2018 press conference about how recent advances are providing extraordinary new hope to patients and their families. #Advocacy https://t.co/b2UhGYV8ed |
| Bob Steele @steele_bob RT @jillfeldman4: One of my favorite pics from the conference! #LCSM https://t.co/7FCvD5siMm |
| Brendon Stiles @BrendonStilesMD @IASLC @jillfeldman4 This is KEY, because galvanizing the community and providing hope lead to advocacy...which leads to research funding...which leads to cures. #lcsm #ResearchBeatsCancer |
| Daniel Cadigan @LungRoadAhead #lcsm Looks like it was an incredible conference. So wonderful to see such stellar patient representation there |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD the big story IMO was SCLC - haven’t had any “real” positive trial in 3 decades #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @IASLC @jillfeldman4 This is KEY, because galvanizing the community and providing hope lead to advocacy...which leads to research funding...which leads to cures. #lcsm #ResearchBeatsCancer |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: #lcsm Looks like it was an incredible conference. So wonderful to see such stellar patient representation there |
| Janet Freeman-Daily @JFreemanDaily We had a great Facebook Live event in the #WCLC2018 Patient Advocate Lounge on Sunday evening. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: @BrendonStilesMD the big story IMO was SCLC - haven’t had any “real” positive trial in 3 decades #LCSM |
| Brendon Stiles @BrendonStilesMD @VamsiVelcheti Would love to have seen more benefit, but this is great start. More trials with better selection criteria for IO benefit sure to follow. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We had a great Facebook Live event in the #WCLC2018 Patient Advocate Lounge on Sunday evening. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @tilting Lecia, can you please respond to this? @leciasequist #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @VamsiVelcheti @BrendonStilesMD The applause that broke out in the auditorium after @StephenVLiu presentation was a testament to how much this abstract meant to so many who have dedicated their lives to lung cancer research and patient care #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @VamsiVelcheti @BrendonStilesMD I agree. Definitely practice changing #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: We had a great Facebook Live event in the #WCLC2018 Patient Advocate Lounge on Sunday evening. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @VamsiVelcheti I can't like this enough! @BrendonStilesMD #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @VamsiVelcheti Would love to have seen more benefit, but this is great start. More trials with better selection criteria for IO benefit sure to follow. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Overdue! #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @VamsiVelcheti @BrendonStilesMD The applause that broke out in the auditorium after @StephenVLiu presentation was a testament to how much this abstract meant to so many who have dedicated their lives to lung cancer research and patient care #LCSM |
| Janet Freeman-Daily @JFreemanDaily If you took pictures of the "take-away" slide of a particularly useful presentation, please share! #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD 2 months OS benefit is good but need to do a lot better.. need more SCLC patients going on trials #LCSM |
| Janet Freeman-Daily @JFreemanDaily "OS" is overall survival. S' #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: If you took pictures of the "take-away" slide of a particularly useful presentation, please share! #lcsm |
| Brendon Stiles @BrendonStilesMD @LeciaSequist @VamsiVelcheti @StephenVLiu Plus he is a good looking, well spoken guy! In all seriousness, this was incredibly important for community and will lead to more! #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @VamsiVelcheti @BrendonStilesMD Hasn't been for lack of trying! How many negative trials have we seen? #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: @BrendonStilesMD 2 months OS benefit is good but need to do a lot better.. need more SCLC patients going on trials #LCSM |
| Janet Freeman-Daily @JFreemanDaily "SCLC" is small cell lung cancer. #lcsm |
| IASLC @IASLC #LCSM Chat Tweet 3: IASLC CEO @fred_hirsch speaks about the growing role of #biomarkers at #WCLC2018. #Biology https://t.co/6rJosIWOdM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @IASLC @jillfeldman4 This is KEY, because galvanizing the community and providing hope lead to advocacy...which leads to research funding...which leads to cures. #lcsm #ResearchBeatsCancer |
| Tim Kruser @TimothyKruserMD @tilting We don't approve drugs or treatment based on unplanned post-hoc analyses. Bad science. Similarly shouldn't exclude such pts #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @MedscapeSurgery: Lung cancer patients who refuse surgery face reduced survival odds. https://t.co/esLcUPABWO #WCLC2018 #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: "OS" is overall survival. S' #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: "SCLC" is small cell lung cancer. #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 3: #LCSM Chat Tweet 3: IASLC CEO @fred_hirsch speaks about the growing role of #biomarkers at #WCLC2018. #Biology https://t.co/6rJosIWOdM |
 | Dr. David Tom Cooke @DavidCookeMD RT @MedscapeSurgery: Lung cancer patients who refuse surgery face reduced survival odds. https://t.co/esLcUPABWO #WCLC2018 #LCSM |
| #LCSM Chat @lcsmchat RT @TimothyKruserMD: @tilting We don't approve drugs or treatment based on unplanned post-hoc analyses. Bad science. Similarly shouldn't exclude such pts #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Amazing thing about #wclc2018 was the progress on multiple fronts: Amazing thing about #wclc2018 was the progress on multiple fronts: screening, stage III, small cell, immunotherapy, targeted therapy. Incredible time to be involved in lung cancer. #lcsm |
 | Stephen V Liu, MD @StephenVLiu Remember median is just one point in time. The HR of 0.70 is meaningful in my mind #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @IASLC @jillfeldman4 This is KEY, because galvanizing the community and providing hope lead to advocacy...which leads to research funding...which leads to cures. #lcsm #ResearchBeatsCancer |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #EvidenceBasedMedicine #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @VamsiVelcheti @BrendonStilesMD The applause that broke out in the auditorium after @StephenVLiu presentation was a testament to how much this abstract meant to so many who have dedicated their lives to lung cancer research and patient care #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @StephenVLiu definitely #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: Remember median is just one point in time. The HR of 0.70 is meaningful in my mind #LCSM |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 3: #LCSM Chat Tweet 3: IASLC CEO @fred_hirsch speaks about the growing role of #biomarkers at #WCLC2018. #Biology https://t.co/6rJosIWOdM |
| Brendon Stiles @BrendonStilesMD Can I talk about NELSON ??? Incredible results which will hopefully help increase screening rates! #lcsm https://t.co/WoB3UmM4oW |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: Can I talk about NELSON ??? Incredible results which will hopefully help increase screening rates! #lcsm https://t.co/WoB3UmM4oW |
 | Shelly ET @shelly_et RT @BrendonStilesMD: For me best part of #wclc2018 is always the shared experience with colleagues and patients. Incredible dialogue. #lcsm https://t.co/RreCqHSXXK |
| Brendon Stiles @BrendonStilesMD @StephenVLiu Very true for patients. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: Can I talk about NELSON ??? Incredible results which will hopefully help increase screening rates! #lcsm https://t.co/WoB3UmM4oW |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD There's a tweet coming about NELSON, but feel free to talk about it now! #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily @tilting Great question! The EGFR subgroup was the only one not to have a survival benefit in PACIFIC, tho the sample size was small. I remain nervous about adj IO for stage 3 known EGFR. There was a recent string about this b/w me, @JackWestMD and a few others w/ more details #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Molecular therapy/immunotherapy desperately needed for these patients. #lcsm |
| Anita Figueras @scifiknitter RT @LeciaSequist: @JFreemanDaily @tilting Great question! The EGFR subgroup was the only one not to have a survival benefit in PACIFIC, tho the sample size was small. I remain nervous about adj IO for stage 3 known EGFR. There was a recent string about this b/w me, @JackWestMD and a few others w/ more details #LCSM |
| Janet Freeman-Daily @JFreemanDaily #lungcancer is leading the charge on precision medicine based on biomarkers. Such a dynamic field! #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily @tilting Great question! The EGFR subgroup was the only one not to have a survival benefit in PACIFIC, tho the sample size was small. I remain nervous about adj IO for stage 3 known EGFR. There was a recent string about this b/w me, @JackWestMD and a few others w/ more details #LCSM |
| Bob Steele @steele_bob RT @TimAllenMDJD: Molecular therapy/immunotherapy desperately needed for these patients. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD There's a tweet coming about NELSON, but feel free to talk about it now! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Can I talk about NELSON ??? Incredible results which will hopefully help increase screening rates! #lcsm https://t.co/WoB3UmM4oW |
| Brendon Stiles @BrendonStilesMD @BrendonStilesMD Currently, less than 10% of eligible patients are screened for lung cancer. Modeling suggests that we could save 10s of thousands of lives by getting screening rates comparable to other cancers. We have strong data to support screening. #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: #lungcancer is leading the charge on precision medicine based on biomarkers. Such a dynamic field! #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Molecular therapy/immunotherapy desperately needed for these patients. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #lungcancer is leading the charge on precision medicine based on biomarkers. Such a dynamic field! #lcsm |
| Tim Kruser @TimothyKruserMD @BrendonStilesMD NELSON is great data. We need to get on a family practice or Int Med forum to have it make the biggest impact! #lcsm |
 | Lung Cancer #1 cancer killer of women @VirginiaMByrne Ginny Byrne here #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @BrendonStilesMD Currently, less than 10% of eligible patients are screened for lung cancer. Modeling suggests that we could save 10s of thousands of lives by getting screening rates comparable to other cancers. We have strong data to support screening. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: @BrendonStilesMD Currently, less than 10% of eligible patients are screened for lung cancer. Modeling suggests that we could save 10s of thousands of lives by getting screening rates comparable to other cancers. We have strong data to support screening. #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @BrendonStilesMD Agree! This was my favorite abstract of the meeting! screening uptake in the US has been dismal and this is (hopefully) going to convince some of the skeptics #LCSM |
 | H. Jack West, MD @JackWestMD @LeciaSequist @VamsiVelcheti @BrendonStilesMD @StephenVLiu Agree. IMpower133 probably isn't pinnacle that will define std of care in SCLC for 10+ years, but it broke an impasse & is likely just first of many trials we'll see come back pos for SCLC in next few yrs, IMO. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @TimothyKruserMD: @BrendonStilesMD NELSON is great data. We need to get on a family practice or Int Med forum to have it make the biggest impact! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @VirginiaMByrne Hi Ginny! #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @LeciaSequist: @BrendonStilesMD Agree! This was my favorite abstract of the meeting! screening uptake in the US has been dismal and this is (hopefully) going to convince some of the skeptics #LCSM |
| Jill Feldman @jillfeldman4 @BrendonStilesMD Nelson results exciting, but only small group of women in population study? Yet, women benefited more! #lcsm |
| #LCSM Chat @lcsmchat RT @TimothyKruserMD: @BrendonStilesMD NELSON is great data. We need to get on a family practice or Int Med forum to have it make the biggest impact! #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @BrendonStilesMD: Can I talk about NELSON ??? Incredible results which will hopefully help increase screening rates! #lcsm https://t.co/WoB3UmM4oW |
| IASLC @IASLC #LCSM Chat Tweet 4: Keith Kerr presented on IASLC Blueprint project phase 2B evaluating comparability of PD-L1 scores in fine needle aspirate, biopsy or large surgical resection from same tumor; 24 pathologists scored 31 triplet samples. #WCLC2018 #Immunooncology https://t.co/0r9JHkCQx7 |
 | Darrell Polk 1 @polksbc1 RT @bensolomon1: Thanks @chrisdraft for visiting Australia to share your energy and passion at the ALTG Symposium. Chris with @TommyJohn00 and me - only one of us played in the NFL but all of us doing our best to tackle lung cancer! And (trying) to look tough! #LCSM @Lungfoundation @teamdraft https://t.co/BwFKDPrRYp |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily Indeed. "Lung cancer" is actually many different cancers with individualized treatment needs. Never been more apparent. Our ability to find those differences is increasing. #lcsm |
 | Flemming Rasmussen @fgrazz Listening in from east coast 🇨🇦 #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @BrendonStilesMD Agree! This was my favorite abstract of the meeting! screening uptake in the US has been dismal and this is (hopefully) going to convince some of the skeptics #LCSM |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 4: #LCSM Chat Tweet 4: Keith Kerr presented on IASLC Blueprint project phase 2B evaluating comparability of PD-L1 scores in fine needle aspirate, biopsy or large surgical resection from same tumor; 24 pathologists scored 31 triplet samples. #WCLC2018 #Immunooncology https://t.co/0r9JHkCQx7 |
 | Frank Ingram, MD @Chucktowndoc Ingram here...a little tardy. Community pathologist in NC. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @LeciaSequist @VamsiVelcheti @BrendonStilesMD @StephenVLiu Agree. IMpower133 probably isn't pinnacle that will define std of care in SCLC for 10+ years, but it broke an impasse & is likely just first of many trials we'll see come back pos for SCLC in next few yrs, IMO. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD One huge takeaway, IMHO. #PatientsFirst #NoStigma #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: @BrendonStilesMD Currently, less than 10% of eligible patients are screened for lung cancer. Modeling suggests that we could save 10s of thousands of lives by getting screening rates comparable to other cancers. We have strong data to support screening. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: @BrendonStilesMD Nelson results exciting, but only small group of women in population study? Yet, women benefited more! #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 4: #LCSM Chat Tweet 4: Keith Kerr presented on IASLC Blueprint project phase 2B evaluating comparability of PD-L1 scores in fine needle aspirate, biopsy or large surgical resection from same tumor; 24 pathologists scored 31 triplet samples. #WCLC2018 #Immunooncology https://t.co/0r9JHkCQx7 |
| Daniel Cadigan @LungRoadAhead NELSON results were incredible but really need to get smaller hospitals screening to give more pts access. Too much resistance from radiologists still. Our local just refuses any attempts to put in place #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @JFreemanDaily Indeed. "Lung cancer" is actually many different cancers with individualized treatment needs. Never been more apparent. Our ability to find those differences is increasing. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti RT @JackWestMD: @LeciaSequist @VamsiVelcheti @BrendonStilesMD @StephenVLiu Agree. IMpower133 probably isn't pinnacle that will define std of care in SCLC for 10+ years, but it broke an impasse & is likely just first of many trials we'll see come back pos for SCLC in next few yrs, IMO. #LCSM |
| Betsy @MAmaskwearer RT @TimAllenMDJD: One huge takeaway, IMHO. #PatientsFirst #NoStigma #lcsm |
| Brendon Stiles @BrendonStilesMD @jillfeldman4 Yes. Lots of discussion about this. Need more screening of at risk populations including women. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @LungRoadAhead: NELSON results were incredible but really need to get smaller hospitals screening to give more pts access. Too much resistance from radiologists still. Our local just refuses any attempts to put in place #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @LeciaSequist @JFreemanDaily @tilting @JackWestMD Only about 40 pts combined, wouldn’t conclude much from this! #lcsm |
| Janet Freeman-Daily @JFreemanDaily If you're just watching tonight's chat, remember to tweet “#LCSM” so we know you’re in the audience. But we're a friendly bunch ... #lcsm |
| Bob Steele @steele_bob @Chucktowndoc Glad to see another Tarheel on LCSM #lcsm |
| Daniel Cadigan @LungRoadAhead Also, the strict requirements such as having an oncologist on review panel have limited smaller hospitals participating in screening. As a family practice doc, I am capable of interpreting a CT report and advising a patient and then making the referral if needed. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @jillfeldman4 Yes. Lots of discussion about this. Need more screening of at risk populations including women. #lcsm |
| Flemming Rasmussen @fgrazz RT @LungCancerFaces: @tilting Welcome! You're among friends here. #lcsm |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: NELSON results were incredible but really need to get smaller hospitals screening to give more pts access. Too much resistance from radiologists still. Our local just refuses any attempts to put in place #LCSM |
 | Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @StephenVLiu: Remember median is just one point in time. The HR of 0.70 is meaningful in my mind #LCSM |
 | SunshineKK @SunshineKK68 #lcsm |
| Brendon Stiles @BrendonStilesMD @IASLC This is soooooo important to understand how FNA reflects entire tumor for IO, but also for targeted therapies. Also need to know how PD-L1 changes in response to therapy. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: If you're just watching tonight's chat, remember to tweet “#LCSM” so we know you’re in the audience. But we're a friendly bunch ... #lcsm |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: Also, the strict requirements such as having an oncologist on review panel have limited smaller hospitals participating in screening. As a family practice doc, I am capable of interpreting a CT report and advising a patient and then making the referral if needed. #lcsm |
| Janet Freeman-Daily @JFreemanDaily We have a great group of #lungcancer professionals on here tonight. Would love to hear your takes of what caught your eye at #WCLC2018 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @IASLC This is soooooo important to understand how FNA reflects entire tumor for IO, but also for targeted therapies. Also need to know how PD-L1 changes in response to therapy. #lcsm |
| H. Jack West, MD @JackWestMD @LeciaSequist @JFreemanDaily @tilting Many of us have mixed feelings. I understand hesitation @LeciaSequist & some others feel. It's risk of harm & non-benefit vs. Q of whether pts in overall pos trial should be excluded based on subset analysis, which is weak science. Tough Q, need more info. #LCSM |
| Anita Figueras @scifiknitter RT @LeciaSequist: @BrendonStilesMD Agree! This was my favorite abstract of the meeting! screening uptake in the US has been dismal and this is (hopefully) going to convince some of the skeptics #LCSM |
| Bob Steele @steele_bob RT @JFreemanDaily: We have a great group of #lungcancer professionals on here tonight. Would love to hear your takes of what caught your eye at #WCLC2018 #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We have a great group of #lungcancer professionals on here tonight. Would love to hear your takes of what caught your eye at #WCLC2018 #lcsm |
 | Jose F. Corona-Cruz MD @drcoronacruz RT @IASLC: #LCSM Chat Tweet 4: #LCSM Chat Tweet 4: Keith Kerr presented on IASLC Blueprint project phase 2B evaluating comparability of PD-L1 scores in fine needle aspirate, biopsy or large surgical resection from same tumor; 24 pathologists scored 31 triplet samples. #WCLC2018 #Immunooncology https://t.co/0r9JHkCQx7 |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @bensolomon1: Thanks @chrisdraft for visiting Australia to share your energy and passion at the ALTG Symposium. Chris with @TommyJohn00 and me - only one of us played in the NFL but all of us doing our best to tackle lung cancer! And (trying) to look tough! #LCSM @Lungfoundation @teamdraft https://t.co/BwFKDPrRYp |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD But tumor heterogeneity... Big challenge. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @SunshineKK68 Welcome! #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD The data on molecularly driven targeted therapy, especially in MET exon 14 mutant tumors was impressive #lcsm |
| Tim Kruser @TimothyKruserMD @tilting I believe that is correct. I'd point out it was ~20% of pts, the Durvalumab has limited toxicity, & RT is known to increase PD-L1 expression. Bx was before RT. I'd want my patient to get the drug. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @LeciaSequist @JFreemanDaily @tilting Many of us have mixed feelings. I understand hesitation @LeciaSequist & some others feel. It's risk of harm & non-benefit vs. Q of whether pts in overall pos trial should be excluded based on subset analysis, which is weak science. Tough Q, need more info. #LCSM |
| Daniel Cadigan @LungRoadAhead Only one hospital of the three within a 30 mile radius of my practice offers screening at this point. And it’s the largest hospital #lcsm |
| Bob Steele @steele_bob RT @CharuAggarwalMD: The data on molecularly driven targeted therapy, especially in MET exon 14 mutant tumors was impressive #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: @jillfeldman4 Yes. Lots of discussion about this. Need more screening of at risk populations including women. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: @LeciaSequist @JFreemanDaily @tilting Many of us have mixed feelings. I understand hesitation @LeciaSequist & some others feel. It's risk of harm & non-benefit vs. Q of whether pts in overall pos trial should be excluded based on subset analysis, which is weak science. Tough Q, need more info. #LCSM |
| IASLC @IASLC RT @JFreemanDaily: We have a great group of #lungcancer professionals on here tonight. Would love to hear your takes of what caught your eye at #WCLC2018 #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: But tumor heterogeneity... Big challenge. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD: @LeciaSequist @JFreemanDaily @tilting Many of us have mixed feelings. I understand hesitation @LeciaSequist & some others feel. It's risk of harm & non-benefit vs. Q of whether pts in overall pos trial should be excluded based on subset analysis, which is weak science. Tough Q, need more info. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: The data on molecularly driven targeted therapy, especially in MET exon 14 mutant tumors was impressive #lcsm |
| #LCSM Chat @lcsmchat RT @TimothyKruserMD: @tilting I believe that is correct. I'd point out it was ~20% of pts, the Durvalumab has limited toxicity, & RT is known to increase PD-L1 expression. Bx was before RT. I'd want my patient to get the drug. #lcsm |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: Only one hospital of the three within a 30 mile radius of my practice offers screening at this point. And it’s the largest hospital #lcsm |
| Bob Steele @steele_bob RT @TimAllenMDJD: But tumor heterogeneity... Big challenge. #lcsm |
| Brendon Stiles @BrendonStilesMD And I have to express my love for PACIFIC and for moving IO into earlier stage trials. Could be game changing and should cure more patients. Yes, cure. #lcsm https://t.co/4zAu6koOVX |
| Lecia Sequist, MD, MPH @LeciaSequist @LungRoadAhead We are doing so poorly with lung cancer screening, there is plenty of blame to go around. Need improvements in systems, patient navigation, access, cost, PCP buy-in, patient buy-in, decrease shared decision-making barriers, and so much more #LCSM |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD For sure. #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @LeciaSequist: @JFreemanDaily @tilting Great question! The EGFR subgroup was the only one not to have a survival benefit in PACIFIC, tho the sample size was small. I remain nervous about adj IO for stage 3 known EGFR. There was a recent string about this b/w me, @JackWestMD and a few others w/ more details #LCSM |
| IASLC @IASLC #LCSM Chat Tweet 5: Our president, @giorgioscaglio3, delivers unfortunate phase III results from the LUME-Meso trial at the #WCLC2018 Presidential Symposium. Trial did not meet primary endpoint and other endpoints showed no difference between treatment groups. #Mesothelioma https://t.co/oPlFYolHqu |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 5: #LCSM Chat Tweet 5: Our president, @giorgioscaglio3, delivers unfortunate phase III results from the LUME-Meso trial at the #WCLC2018 Presidential Symposium. Trial did not meet primary endpoint and other endpoints showed no difference between treatment groups. #Mesothelioma https://t.co/oPlFYolHqu |
| Dr. David Tom Cooke @DavidCookeMD RT @LeciaSequist: @LungRoadAhead We are doing so poorly with lung cancer screening, there is plenty of blame to go around. Need improvements in systems, patient navigation, access, cost, PCP buy-in, patient buy-in, decrease shared decision-making barriers, and so much more #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @BrendonStilesMD @jillfeldman4 Not sure why the trial was designed that way, but women greatly benefit from screening. Major takeaway from the meeting #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: And I have to express my love for PACIFIC and for moving IO into earlier stage trials. Could be game changing and should cure more patients. Yes, cure. #lcsm https://t.co/4zAu6koOVX |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @LungRoadAhead We are doing so poorly with lung cancer screening, there is plenty of blame to go around. Need improvements in systems, patient navigation, access, cost, PCP buy-in, patient buy-in, decrease shared decision-making barriers, and so much more #LCSM |
| Brendon Stiles @BrendonStilesMD @IASLC @giorgioscaglio3 A sobering bummer to an otherwise incredible morning. We have to break through in mesothelioma. #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 5: #LCSM Chat Tweet 5: Our president, @giorgioscaglio3, delivers unfortunate phase III results from the LUME-Meso trial at the #WCLC2018 Presidential Symposium. Trial did not meet primary endpoint and other endpoints showed no difference between treatment groups. #Mesothelioma https://t.co/oPlFYolHqu |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Meso remains tough. #lcsm |
 | Yesenia Huerta-Collado @YeseniaOrifiel RT @IASLC: #LCSM Chat Tweet 4: #LCSM Chat Tweet 4: Keith Kerr presented on IASLC Blueprint project phase 2B evaluating comparability of PD-L1 scores in fine needle aspirate, biopsy or large surgical resection from same tumor; 24 pathologists scored 31 triplet samples. #WCLC2018 #Immunooncology https://t.co/0r9JHkCQx7 |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD @jillfeldman4 Not sure why the trial was designed that way, but women greatly benefit from screening. Major takeaway from the meeting #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: @IASLC @giorgioscaglio3 A sobering bummer to an otherwise incredible morning. We have to break through in mesothelioma. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @IASLC @giorgioscaglio3 A sobering bummer to an otherwise incredible morning. We have to break through in mesothelioma. #lcsm |
| IASLC @IASLC RT @LungRoadAhead: Only one hospital of the three within a 30 mile radius of my practice offers screening at this point. And it’s the largest hospital #lcsm |
| Anita Figueras @scifiknitter RT @LungRoadAhead: Also, the strict requirements such as having an oncologist on review panel have limited smaller hospitals participating in screening. As a family practice doc, I am capable of interpreting a CT report and advising a patient and then making the referral if needed. #lcsm |
| IASLC @IASLC RT @LeciaSequist: @LungRoadAhead We are doing so poorly with lung cancer screening, there is plenty of blame to go around. Need improvements in systems, patient navigation, access, cost, PCP buy-in, patient buy-in, decrease shared decision-making barriers, and so much more #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD I long for cure, but fear continued tumor acquired resistance will be tough to overcome. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @IASLC @giorgioscaglio3 I was so hoping to hear mesothelioma had a new treatment option. :( #lcsm |
| Bob Steele @steele_bob RT @TimAllenMDJD: I long for cure, but fear continued tumor acquired resistance will be tough to overcome. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: I long for cure, but fear continued tumor acquired resistance will be tough to overcome. #lcsm |
| Brendon Stiles @BrendonStilesMD Lots happening in the ALK world. One great drug after another. Biopsied a 47 yo never smoker with apparent stage IV disease today and HOPING she has an ALK rearrangement. Mucinous features. #lcsm https://t.co/NoN4wZsyQN |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Keith Kerr FTW! Stellar pulmonary pathologist. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Lots happening in the ALK world. One great drug after another. Biopsied a 47 yo never smoker with apparent stage IV disease today and HOPING she has an ALK rearrangement. Mucinous features. #lcsm https://t.co/NoN4wZsyQN |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD I think we can cure some stage III patients. #lcsm. |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD impressive but lot of questions- 1) role of surgery in low volume stg 3A 2) PDL1 0%??? lack of benefit (post hoc analysis) 3) EGFR/ALK pts? #LCSM |
| Lung Cancer Sux @LungCancerSux @LungRoadAhead « There’s an exception to every rule » #lcsm |
| IASLC @IASLC #LCSM Chat Tweet 6: Jenny Mitchell of @OUHospitals outlines an innovative, nurse-led telephone clinic, designed to assist in long-term follow-up following thoracic cancer surgery. #WCLC2018 #Nursing https://t.co/BxgZFp1hk8 |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD I see you are focusing on the positives here @BrendonStilesMD @TimAllenMDJD :) #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Lots happening in the ALK world. One great drug after another. Biopsied a 47 yo never smoker with apparent stage IV disease today and HOPING she has an ALK rearrangement. Mucinous features. #lcsm https://t.co/NoN4wZsyQN |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: @BrendonStilesMD impressive but lot of questions- 1) role of surgery in low volume stg 3A 2) PDL1 0%??? lack of benefit (post hoc analysis) 3) EGFR/ALK pts? #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #hope #lcsm |
| Daniel Cadigan @LungRoadAhead Agree. But the biggest thing to getting numbers increased is simply asking patients to be screen. I have not had one patient that qualifies that I have suggested screening to refuse to be screened #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 6: #LCSM Chat Tweet 6: Jenny Mitchell of @OUHospitals outlines an innovative, nurse-led telephone clinic, designed to assist in long-term follow-up following thoracic cancer surgery. #WCLC2018 #Nursing https://t.co/BxgZFp1hk8 |
| Brendon Stiles @BrendonStilesMD @VamsiVelcheti Agree with all questions. Surgery should still have a role at this point. Anxious about drug in PDL1 0% and EGFR.ALK. #lcsm |
| Jill Feldman @jillfeldman4 There will always be concerns & challenges research, but #WCLC2018 was full of passion, dedication, new developments, collaboration & patient focus... which translates to the Hope that lc patients & our families have desperately needed! #LCSM |
 | Stacy Grieve @CancerUncovered @CharuAggarwalMD @BrendonStilesMD @jillfeldman4 Given the emphasis that sex and gender should now play in our research, appreciated that this was the only study at the meeting to discuss differences between men and women #lcsm |
| Bob Steele @steele_bob Which topic/Tx reported the greatest progress? #lcsm |
| Brendon Stiles @BrendonStilesMD @CharuAggarwalMD @TimAllenMDJD For sure. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #hope #lcsm |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 6: #LCSM Chat Tweet 6: Jenny Mitchell of @OUHospitals outlines an innovative, nurse-led telephone clinic, designed to assist in long-term follow-up following thoracic cancer surgery. #WCLC2018 #Nursing https://t.co/BxgZFp1hk8 |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: Agree. But the biggest thing to getting numbers increased is simply asking patients to be screen. I have not had one patient that qualifies that I have suggested screening to refuse to be screened #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @VamsiVelcheti Agree with all questions. Surgery should still have a role at this point. Anxious about drug in PDL1 0% and EGFR.ALK. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: There will always be concerns & challenges research, but #WCLC2018 was full of passion, dedication, new developments, collaboration & patient focus... which translates to the Hope that lc patients & our families have desperately needed! #LCSM |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD need a study for respectable stg 3A with post op adj IO #LCSM |
| Janet Freeman-Daily @JFreemanDaily @steele_bob I can't say any ONE tx had the most progress, but we had data on THREE ROS1+ NSCLC drugs--that's progress to me! #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @LungRoadAhead: Agree. But the biggest thing to getting numbers increased is simply asking patients to be screen. I have not had one patient that qualifies that I have suggested screening to refuse to be screened #lcsm |
| #LCSM Chat @lcsmchat RT @CancerUncovered: @CharuAggarwalMD @BrendonStilesMD @jillfeldman4 Given the emphasis that sex and gender should now play in our research, appreciated that this was the only study at the meeting to discuss differences between men and women #lcsm |
| IASLC @IASLC RT @jillfeldman4: There will always be concerns & challenges research, but #WCLC2018 was full of passion, dedication, new developments, collaboration & patient focus... which translates to the Hope that lc patients & our families have desperately needed! #LCSM |
| #LCSM Chat @lcsmchat RT @steele_bob: Which topic/Tx reported the greatest progress? #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: @steele_bob I can't say any ONE tx had the most progress, but we had data on THREE ROS1+ NSCLC drugs--that's progress to me! #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Anti angiogenesis has had a checkered history in #mesothelioma. Tough populaiton @IASLC @giorgioscaglio3 #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @steele_bob I can't say any ONE tx had the most progress, but we had data on THREE ROS1+ NSCLC drugs--that's progress to me! #lcsm |
| Anita Figueras @scifiknitter RT @TimAllenMDJD: I long for cure, but fear continued tumor acquired resistance will be tough to overcome. #lcsm |
| Bob Steele @steele_bob RT @VamsiVelcheti: @BrendonStilesMD need a study for respectable stg 3A with post op adj IO #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Anti angiogenesis has had a checkered history in #mesothelioma. Tough populaiton @IASLC @giorgioscaglio3 #LCSM |
| Janet Freeman-Daily @JFreemanDaily Also appreciated seeing @LCAorg presentation on needs of long-term stage 4 #lungcancer survivors--in Sunday press conference! #lcsm |
| Bob Steele @steele_bob RT @CharuAggarwalMD: Anti angiogenesis has had a checkered history in #mesothelioma. Tough populaiton @IASLC @giorgioscaglio3 #LCSM |
| Brendon Stiles @BrendonStilesMD @VamsiVelcheti Great niche with lots in the works. We have a durva study (neoadj + adj) that includes resectable IIIA. One arm gets non ablative RT. Had a IIIA patient with CPR just last week. #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: Also appreciated seeing @LCAorg presentation on needs of long-term stage 4 #lungcancer survivors--in Sunday press conference! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Also appreciated seeing @LCAorg presentation on needs of long-term stage 4 #lungcancer survivors--in Sunday press conference! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @VamsiVelcheti Great niche with lots in the works. We have a durva study (neoadj + adj) that includes resectable IIIA. One arm gets non ablative RT. Had a IIIA patient with CPR just last week. #lcsm |
| Anita Figueras @scifiknitter RT @IASLC: #LCSM Chat Tweet 6: #LCSM Chat Tweet 6: Jenny Mitchell of @OUHospitals outlines an innovative, nurse-led telephone clinic, designed to assist in long-term follow-up following thoracic cancer surgery. #WCLC2018 #Nursing https://t.co/BxgZFp1hk8 |
| IASLC @IASLC #LCSM Chat Tweet 7: Amazing presentation at the #WCLC2018 Presidential Symposium of NELSON mortality results. A wonderful result showing a substantial reduction in #lungcancer mortality in both genders. #EarlyDetection #Screening https://t.co/A8UjkOyTYu |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 7: #LCSM Chat Tweet 7: Amazing presentation at the #WCLC2018 Presidential Symposium of NELSON mortality results. A wonderful result showing a substantial reduction in #lungcancer mortality in both genders. #EarlyDetection #Screening https://t.co/A8UjkOyTYu |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Also appreciated seeing @LCAorg presentation on needs of long-term stage 4 #lungcancer survivors--in Sunday press conference! #lcsm |
| Flemming Rasmussen @fgrazz @BrendonStilesMD @IASLC @giorgioscaglio3 #Meso - Overdue to make some investments in completely different paths? #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 7: #LCSM Chat Tweet 7: Amazing presentation at the #WCLC2018 Presidential Symposium of NELSON mortality results. A wonderful result showing a substantial reduction in #lungcancer mortality in both genders. #EarlyDetection #Screening https://t.co/A8UjkOyTYu |
| Bob Steele @steele_bob RT @fgrazz: @BrendonStilesMD @IASLC @giorgioscaglio3 #Meso - Overdue to make some investments in completely different paths? #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @steele_bob Lung Cancer Screening. Prevention is MUCH better than cure. I think NELSON was the greatest progress #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @VamsiVelcheti Great niche with lots in the works. We have a durva study (neoadj + adj) that includes resectable IIIA. One arm gets non ablative RT. Had a IIIA patient with CPR just last week. #lcsm |
| #LCSM Chat @lcsmchat RT @fgrazz: @BrendonStilesMD @IASLC @giorgioscaglio3 #Meso - Overdue to make some investments in completely different paths? #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @IASLC: #LCSM Chat Tweet 7: #LCSM Chat Tweet 7: Amazing presentation at the #WCLC2018 Presidential Symposium of NELSON mortality results. A wonderful result showing a substantial reduction in #lungcancer mortality in both genders. #EarlyDetection #Screening https://t.co/A8UjkOyTYu |
| Peggy Dennis @peggyddennis #LCSM wouldn't it be great if there were progress for those of us who are not EGFR, ALK, ROS1 and <1% PD1 |
| Flemming Rasmussen @fgrazz @BrendonStilesMD @IASLC @giorgioscaglio3 Even with extremely bright minds, progress seems so elusive #LCSM |
| Bob Steele @steele_bob RT @CharuAggarwalMD: @steele_bob Lung Cancer Screening. Prevention is MUCH better than cure. I think NELSON was the greatest progress #LCSM |
| Anita Figueras @scifiknitter RT @JFreemanDaily: Also appreciated seeing @LCAorg presentation on needs of long-term stage 4 #lungcancer survivors--in Sunday press conference! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Moving in the right direction! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hey @BrendonStilesMD -- here's your NELSON tweet! #LCSM |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD we are right across the street we should talk more 😀 #LCSM would love to collaborate on some perioperative trials |
| #LCSM Chat @lcsmchat RT @peggyddennis: #LCSM wouldn't it be great if there were progress for those of us who are not EGFR, ALK, ROS1 and <1% PD1 |
| Brendon Stiles @BrendonStilesMD #wclc2018 is also great meeting for cross disciplinary discussions and collaborations. These guys treat me tough on Twitter, but we all just melt when we see each other. #lcsm https://t.co/M46TuLjeh4 |
| Daniel Cadigan @LungRoadAhead As soon as I saw that data come up, I was texting the numbers to our hospitals COO asking why we let our radiologist run the show again? He did say that hopefully things will change regarding screening soon for us. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #KeepCalmAndCarryOn #LCSM |
| #LCSM Chat @lcsmchat Yes, early detection is key. #lcsm |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily #lcsm👏👏👏 ❤️❤️❤️ |
 | Andrea Borondy Kitts @findlungcancer Cancer-related pain management in clinical oncology https://t.co/udrhy03iRo #lcsm #bcsm |
| Brendon Stiles @BrendonStilesMD @VamsiVelcheti Let’s do it. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #wclc2018 is also great meeting for cross disciplinary discussions and collaborations. These guys treat me tough on Twitter, but we all just melt when we see each other. #lcsm https://t.co/M46TuLjeh4 |
| Bob Steele @steele_bob I retweet a lot. Have lots of lung cancer Twitter friends/followers that don't join in. I/we need to fix that! #lcsm |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: As soon as I saw that data come up, I was texting the numbers to our hospitals COO asking why we let our radiologist run the show again? He did say that hopefully things will change regarding screening soon for us. #lcsm |
| Andrea Borondy Kitts @findlungcancer Sleep disorders in patients with cancer https://t.co/02E4GQodwS #lcsm #bcsm |
| Brendon Stiles @BrendonStilesMD Look at @DrewMoghanaki. He looks so happy and content. #lcsm |
| Bob Steele @steele_bob RT @findlungcancer: Cancer-related pain management in clinical oncology https://t.co/udrhy03iRo #lcsm #bcsm |
| Jill Feldman @jillfeldman4 A non invasive, cost effective, universal tool for screening is still desperately needed! #lcsm |
 | Sanjay Popat @DrSanjayPopat @BrendonStilesMD @JFreemanDaily @TimAllenMDJD Pathology is the cornerstone of treating #nsclc. Understanding the morphological features, the IHC, and the genomic features of a tumor helps us better understand its natural history #LCSM @PulmPathSoc #pulmpath |
| Bob Steele @steele_bob RT @findlungcancer: Sleep disorders in patients with cancer https://t.co/02E4GQodwS #lcsm #bcsm |
| Janet Freeman-Daily @JFreemanDaily @findlungcancer Hey, Andrea--where are you? It's time for #LCSM Chat! |
| IASLC @IASLC #LCSM Chat Tweet 8: Stephen V. Liu delivers a major presentation at the #WCLC2018 Presidential Symposium. It has been over 20 years, but IMpower 133 has now demonstrated clinically-meaningful improvement in OS over current standard-of-care for ES-SCLC. #SCLC https://t.co/QKIrPQLHRD |
| #LCSM Chat @lcsmchat RT @jillfeldman4: A non invasive, cost effective, universal tool for screening is still desperately needed! #lcsm |
| Andrea Borondy Kitts @findlungcancer Adverse events from systemic treatment of cancer and patient-reported quality of life https://t.co/4iSCfCdp6z #lcsm #bcsm |
| #LCSM Chat @lcsmchat RT @DrSanjayPopat: @BrendonStilesMD @JFreemanDaily @TimAllenMDJD Pathology is the cornerstone of treating #nsclc. Understanding the morphological features, the IHC, and the genomic features of a tumor helps us better understand its natural history #LCSM @PulmPathSoc #pulmpath |
 | Tricia Braun @Tricia_Braun RT @JFreemanDaily: Hey @BrendonStilesMD -- here's your NELSON tweet! #LCSM |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 8: #LCSM Chat Tweet 8: Stephen V. Liu delivers a major presentation at the #WCLC2018 Presidential Symposium. It has been over 20 years, but IMpower 133 has now demonstrated clinically-meaningful improvement in OS over current standard-of-care for ES-SCLC. #SCLC https://t.co/QKIrPQLHRD |
| Dr. David Tom Cooke @DavidCookeMD RT @lcsmchat: Yes, early detection is key. #lcsm |
| Bob Steele @steele_bob RT @findlungcancer: Adverse events from systemic treatment of cancer and patient-reported quality of life https://t.co/4iSCfCdp6z #lcsm #bcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @CharuAggarwalMD: @steele_bob Lung Cancer Screening. Prevention is MUCH better than cure. I think NELSON was the greatest progress #LCSM |
| Daniel Cadigan @LungRoadAhead We need mobile CT units for screening travelling to rural areas and underserved metro areas offering LC screening just like the Mammovans do for breast #lcsm. Staff with a PA to do the counseling right at the moment #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 8: #LCSM Chat Tweet 8: Stephen V. Liu delivers a major presentation at the #WCLC2018 Presidential Symposium. It has been over 20 years, but IMpower 133 has now demonstrated clinically-meaningful improvement in OS over current standard-of-care for ES-SCLC. #SCLC https://t.co/QKIrPQLHRD |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: We need mobile CT units for screening travelling to rural areas and underserved metro areas offering LC screening just like the Mammovans do for breast #lcsm. Staff with a PA to do the counseling right at the moment #lcsm |
| Brendon Stiles @BrendonStilesMD And this was even after MISSILE.... (Sorry, couldn't help it.) #lcsm https://t.co/RVnwu5Id70 |
| Brendon Stiles @BrendonStilesMD @DrSanjayPopat @JFreemanDaily @TimAllenMDJD @PulmPathSoc Well said. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Can't argue with @DrSanjayPopat ! #lcsm #WhyPathologistsMatter |
| Frank Ingram, MD @Chucktowndoc 🤜🤛🙏 #pathology #lcsm #pulmpath |
| Lecia Sequist, MD, MPH @LeciaSequist @peggyddennis There has been great progress for such patients this year! KN189 in NEJM was a big one (carbo/pem/pembro). At WCLC there was info from IMpower132 for carbo/pem/atezo and PDL1 neg also did well there. #LCSM |
 | Paula Ashton @paulalv RT @LeciaSequist: @LungRoadAhead We are doing so poorly with lung cancer screening, there is plenty of blame to go around. Need improvements in systems, patient navigation, access, cost, PCP buy-in, patient buy-in, decrease shared decision-making barriers, and so much more #LCSM |
| Daniel Cadigan @LungRoadAhead Nobody is allowed to have a pain med anymore. Illegal heroin/fentanyl issues harming access for legit ca pain pts. #lcsm |
| Vamsi Velcheti, MD @VamsiVelcheti Great presentation by @StephenVLiu landmark #Clinicaltrial #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Great concept! We can use #Telemedicine! #PatientsFirst #LCSM |
| Dr. David Tom Cooke @DavidCookeMD In regards to mobile #LungCancerScreening CT units, What about the follow up of all the indeterminate nodules? #LCSM |
| Betsy @MAmaskwearer STIGMA #lcsm |
| #LCSM Chat @lcsmchat @TimAllenMDJD @DrSanjayPopat We need to do a chat on pulmonary pathology, don't you think? #lcsm |
 | Aparna Hegde, MD @notahedge #LCSM joining late Phase I fellow, MDACC |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @peggyddennis There has been great progress for such patients this year! KN189 in NEJM was a big one (carbo/pem/pembro). At WCLC there was info from IMpower132 for carbo/pem/atezo and PDL1 neg also did well there. #LCSM |
| Stephen V Liu, MD @StephenVLiu @VamsiVelcheti @StephenVLiu Thanks! #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @IASLC An oasis in the desert of SCLC negative trials @StephenVLiu #LCSM |
| Bob Steele @steele_bob RT @DavidCookeMD: In regards to mobile #LungCancerScreening CT units, What about the follow up of all the indeterminate nodules? #LCSM |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: Nobody is allowed to have a pain med anymore. Illegal heroin/fentanyl issues harming access for legit ca pain pts. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: Great presentation by @StephenVLiu landmark #Clinicaltrial #LCSM |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: In regards to mobile #LungCancerScreening CT units, What about the follow up of all the indeterminate nodules? #LCSM |
| Brendon Stiles @BrendonStilesMD @lcsmchat @TimAllenMDJD @DrSanjayPopat Absolutely. It is a lot sexier topic than one might expect. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @apassaroMD: A day to remember for #LCSM community @NEJM published today: A day to remember for #LCSM community @NEJM published today: 1️⃣IMpower133:1L of Atezolizumab in SCLC.PFS+/OS+ 2️⃣ALTA-1L Brigatinib vs crizotinib in ALK+.PFS+ 3️⃣Pacific: durvalumab in loc advanced NSCLC. PFS+/OS+ 4️⃣KN407: 1L Pembro+CT Sq PSF+/OS+ #WCLC2018 @IASLC |
| Paula Ashton @paulalv RT @TimothyKruserMD: @BrendonStilesMD NELSON is great data. We need to get on a family practice or Int Med forum to have it make the biggest impact! #lcsm |
| Betsy @MAmaskwearer RT @LungRoadAhead: Nobody is allowed to have a pain med anymore. Illegal heroin/fentanyl issues harming access for legit ca pain pts. #lcsm |
| Paula Ashton @paulalv RT @BrendonStilesMD: @BrendonStilesMD Currently, less than 10% of eligible patients are screened for lung cancer. Modeling suggests that we could save 10s of thousands of lives by getting screening rates comparable to other cancers. We have strong data to support screening. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @apassaroMD: A day to remember for #LCSM community @NEJM published today: 1️⃣IMpower133:1L of Atezolizumab in SCLC.PFS+/OS+… https://t.co/gLo7Jg8upa |
| Vamsi Velcheti, MD @VamsiVelcheti @BrendonStilesMD @DrSanjayPopat @JFreemanDaily @TimAllenMDJD @PulmPathSoc yes too bad we don’t have our wonderful #LCSM thoracic pathologists @smlungpathguy join the discussion tonight |
| Jill Feldman @jillfeldman4 RT @apassaroMD: A day to remember for #LCSM community @NEJM published today: A day to remember for #LCSM community @NEJM published today: 1️⃣IMpower133:1L of Atezolizumab in SCLC.PFS+/OS+ 2️⃣ALTA-1L Brigatinib vs crizotinib in ALK+.PFS+ 3️⃣Pacific: durvalumab in loc advanced NSCLC. PFS+/OS+ 4️⃣KN407: 1L Pembro+CT Sq PSF+/OS+ #WCLC2018 @IASLC |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: RT @apassaroMD: A day to remember for #LCSM community @NEJM published today: RT @apassaroMD: A day to remember for #LCSM community @NEJM published today: 1️⃣IMpower133:1L of Atezolizumab in SCLC.PFS+/OS+… https://t.co/gLo7Jg8upa |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Can't argue with @DrSanjayPopat ! #lcsm #WhyPathologistsMatter |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD I think so! But #bias :-) #lcsm |
| Bob Steele @steele_bob RT @apassaroMD: A day to remember for #LCSM community @NEJM published today: A day to remember for #LCSM community @NEJM published today: 1️⃣IMpower133:1L of Atezolizumab in SCLC.PFS+/OS+ 2️⃣ALTA-1L Brigatinib vs crizotinib in ALK+.PFS+ 3️⃣Pacific: durvalumab in loc advanced NSCLC. PFS+/OS+ 4️⃣KN407: 1L Pembro+CT Sq PSF+/OS+ #WCLC2018 @IASLC |
| Lung Cancer #1 cancer killer of women @VirginiaMByrne RT @TimAllenMDJD: One huge takeaway, IMHO. #PatientsFirst #NoStigma #lcsm |
| IASLC @IASLC #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: “New treatments will only work if patients have an opportunity to receive them.” #WCLC2018 #TargetedTherapies https://t.co/4U7zgw3gXk |
| Frank Ingram, MD @Chucktowndoc RT @TimAllenMDJD: I think so! But #bias :-) #lcsm |
| Paula Ashton @paulalv RT @BrendonStilesMD: The patient advocacy/focused mutation groups are doing incredible work. @EGFRResisters @ALKLungCancer @ros1cancer #lcsm |
 | onthemark @tilting @DrSanjayPopat @BrendonStilesMD @JFreemanDaily @TimAllenMDJD @PulmPathSoc Isn't that the point of TRACERx and the big prize that was given to the leader of that study at #WCLC2018? #lcsm |
| Paula Ashton @paulalv RT @JFreemanDaily: Dr. Doebele had a LOT of presentations, including the data on entrectinib for ROS1+ NSCLC. Hopeful we'll have new tx for @ros1cancer. #lcsm |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: “New treatments will only work if patients have an opportunity to receive them.” #WCLC2018 #TargetedTherapies https://t.co/4U7zgw3gXk |
| Brendon Stiles @BrendonStilesMD Current tweeting situation. Never to young to start getting lung cancer info. #LCSM https://t.co/i9DaITYZk3 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD I prefer "educational and enlightening". #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: “New treatments will only work if patients have an opportunity to receive them.” #WCLC2018 #TargetedTherapies https://t.co/4U7zgw3gXk |
| Anita Figueras @scifiknitter RT @IASLC: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: “New treatments will only work if patients have an opportunity to receive them.” #WCLC2018 #TargetedTherapies https://t.co/4U7zgw3gXk |
| #LCSM Chat @lcsmchat RT @tilting: @DrSanjayPopat @BrendonStilesMD @JFreemanDaily @TimAllenMDJD @PulmPathSoc Isn't that the point of TRACERx and the big prize that was given to the leader of that study at #WCLC2018? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Current tweeting situation. Never to young to start getting lung cancer info. #LCSM https://t.co/i9DaITYZk3 |
| Bob Steele @steele_bob RT @BrendonStilesMD: Current tweeting situation. Never to young to start getting lung cancer info. #LCSM https://t.co/i9DaITYZk3 |
 | Sanjay Mukhopadhyay @smlungpathguy RT @DrSanjayPopat: @BrendonStilesMD @JFreemanDaily @TimAllenMDJD Pathology is the cornerstone of treating #nsclc. Understanding the morphological features, the IHC, and the genomic features of a tumor helps us better understand its natural history #LCSM @PulmPathSoc #pulmpath |
| #LCSM Chat @lcsmchat @BrendonStilesMD Work/life balance is everything. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Amen to this! NSCLC patients need access to genomic testing, but it does no good if we can't access the appropriate meds. #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: I prefer "educational and enlightening". #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @IASLC: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: #LCSM Chat Tweet 9: Dr. Boyer outlines the complexity and ongoing challenges of the new advances in targeted therapy: “New treatments will only work if patients have an opportunity to receive them.” #WCLC2018 #TargetedTherapies https://t.co/4U7zgw3gXk |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Amen to this! NSCLC patients need access to genomic testing, but it does no good if we can't access the appropriate meds. #LCSM |
| Sanjay Popat @DrSanjayPopat @BrendonStilesMD And in the #UK lung cancer screening is not routinely implemented other than a few pilot programs. This must change. Am optimistic following key statements from @10DowningStreet this week #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @DrSanjayPopat: @BrendonStilesMD And in the #UK lung cancer screening is not routinely implemented other than a few pilot programs. This must change. Am optimistic following key statements from @10DowningStreet this week #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Our challenge. Our responsibility. #lcsm |
| Brendon Stiles @BrendonStilesMD Have to drop out! Thanks for all the great work from @IASLC at #wclc2018. It was an astounding meeting that inspired physicians and researchers and brought hope to patients. #lcsm |
| Jill Feldman @jillfeldman4 'Oncology is a Team Sport' - Another favorite slide from #WCLC2018 #LCSM https://t.co/TuzqQeVc29 |
| IASLC @IASLC RT @JFreemanDaily: Amen to this! NSCLC patients need access to genomic testing, but it does no good if we can't access the appropriate meds. #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @peggyddennis I know it can be frustrating. Progress comes one step at a time. Luckily in lung cancer these days the pace of the march has quickened immensely..... #LCSM |
| Anita Figueras @scifiknitter RT @JFreemanDaily: Amen to this! NSCLC patients need access to genomic testing, but it does no good if we can't access the appropriate meds. #LCSM |
| #LCSM Chat @lcsmchat RT @DrSanjayPopat: @BrendonStilesMD And in the #UK lung cancer screening is not routinely implemented other than a few pilot programs. This must change. Am optimistic following key statements from @10DowningStreet this week #LCSM |
| IASLC @IASLC RT @DrSanjayPopat: @BrendonStilesMD And in the #UK lung cancer screening is not routinely implemented other than a few pilot programs. This must change. Am optimistic following key statements from @10DowningStreet this week #LCSM |
| Brendon Stiles @BrendonStilesMD Great chat tonight. Thanks for all the participants, patients and medical professionals. Amazing group. And thanks @JFreemanDaily for moderating. Good night! #lcsm |
| Anita Figueras @scifiknitter RT @jillfeldman4: 'Oncology is a Team Sport' - Another favorite slide from #WCLC2018 #LCSM https://t.co/TuzqQeVc29 |
| Dr. David Tom Cooke @DavidCookeMD Therein lies the rub with poor adoption by PCPs and family medicine. Medical liability for lost track of early potential tumors. #LCSM |
| Daniel Cadigan @LungRoadAhead True issue. All travel screen concepts have a medical director/physician who is responsible for oversight.That persons staff can try to keep contact with the patient. Will always lose some to follow up but better to have screened & lost than never to have screened at all. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: 'Oncology is a Team Sport' - Another favorite slide from #WCLC2018 #LCSM https://t.co/TuzqQeVc29 |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @peggyddennis I know it can be frustrating. Progress comes one step at a time. Luckily in lung cancer these days the pace of the march has quickened immensely..... #LCSM |
| IASLC @IASLC @BrendonStilesMD And thanks for all you do @BrendonStilesMD and all in the #LCSM community! |
| Paula Ashton @paulalv RT @LungRoadAhead: We need mobile CT units for screening travelling to rural areas and underserved metro areas offering LC screening just like the Mammovans do for breast #lcsm. Staff with a PA to do the counseling right at the moment #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: Therein lies the rub with poor adoption by PCPs and family medicine. Medical liability for lost track of early potential tumors. #LCSM |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: True issue. All travel screen concepts have a medical director/physician who is responsible for oversight.That persons staff can try to keep contact with the patient. Will always lose some to follow up but better to have screened & lost than never to have screened at all. #lcsm |
| Frank Ingram, MD @Chucktowndoc We’re all on the same team. #TeamPatient #lcsm |
| IASLC @IASLC RT @jillfeldman4: 'Oncology is a Team Sport' - Another favorite slide from #WCLC2018 #LCSM https://t.co/TuzqQeVc29 |
| IASLC @IASLC #LCSM Chat Tweet 10: @rocketgirlmd delivers a complex and touching talk at #WCLC2018 on her late husband, Paul, their experience when he became afflicted w/ cancer and the resilience that comes when people cultivate meaning in their lives. #LCSM #Survivorship https://t.co/wvUJiWtDrZ |
| Dr. David Tom Cooke @DavidCookeMD RT @IASLC: @BrendonStilesMD And thanks for all you do @BrendonStilesMD and all in the #LCSM community! |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Maybe it's hard, but we need to so both deal with use issues and provide necessary pain relief. #lcsm |
| Paula Ashton @paulalv RT @BrendonStilesMD: For me best part of #wclc2018 is always the shared experience with colleagues and patients. Incredible dialogue. #lcsm https://t.co/RreCqHSXXK |
| Daniel Cadigan @LungRoadAhead But it’s done with mammograms all the time, patients can even self refer. I get results sent to me on patients I haven’t seen in years that &self referred for mammogram & had an abnormality and then I have to follow up on it. It’s already done for that.Not the ideal answer #lcsm |
| Janet Freeman-Daily @JFreemanDaily We're getting near the end of our hour. Time for pithy closing thoughts about #WCLC2018 ... #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD It was a privilege to participate. Thanks, @JFreemanDaily #lcsm |
| Joni Fowler, PharmD, BCPP @jfowlerpharmd @LungRoadAhead Don’t let the perfect be the enemy of the good. #lcsm 🚌 |
| Bob Steele @steele_bob My wife had recurrence of BC, bi-lateral mastectomy & port on 10/25 followed by 2 chemo/2 immuno combo tx. She is still LC advocate #lcsm |
| Sanjay Popat @DrSanjayPopat @BrendonStilesMD @VamsiVelcheti Three more large phase 3 trials on #immunotherapy in ES- SCLC are due to report in 2019. My prediction is that this disease will be transformed #LCSM |
| #LCSM Chat @lcsmchat RT @Chucktowndoc: We’re all on the same team. #TeamPatient #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: #LCSM Chat Tweet 10: #LCSM Chat Tweet 10: @rocketgirlmd delivers a complex and touching talk at #WCLC2018 on her late husband, Paul, their experience when he became afflicted w/ cancer and the resilience that comes when people cultivate meaning in their lives. #LCSM #Survivorship https://t.co/wvUJiWtDrZ |
| Daniel Cadigan @LungRoadAhead Where there is a will there’s a way. We have to find that way. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @IASLC: #LCSM Chat Tweet 10: #LCSM Chat Tweet 10: @rocketgirlmd delivers a complex and touching talk at #WCLC2018 on her late husband, Paul, their experience when he became afflicted w/ cancer and the resilience that comes when people cultivate meaning in their lives. #LCSM #Survivorship https://t.co/wvUJiWtDrZ |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Maybe it's hard, but we need to so both deal with use issues and provide necessary pain relief. #lcsm |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: But it’s done with mammograms all the time, patients can even self refer. I get results sent to me on patients I haven’t seen in years that &self referred for mammogram & had an abnormality and then I have to follow up on it. It’s already done for that.Not the ideal answer #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We're getting near the end of our hour. Time for pithy closing thoughts about #WCLC2018 ... #LCSM |
| #LCSM Chat @lcsmchat RT @jfowlerpharmd: @LungRoadAhead Don’t let the perfect be the enemy of the good. #lcsm 🚌 |
| IASLC @IASLC @JFreemanDaily This is an amazing group and we appreciate each one of you. Thanks for putting aside your time to teach, to learn, and to move progress in #lungcancer forward. #lcsm |
| #LCSM Chat @lcsmchat RT @steele_bob: My wife had recurrence of BC, bi-lateral mastectomy & port on 10/25 followed by 2 chemo/2 immuno combo tx. She is still LC advocate #lcsm |
| #LCSM Chat @lcsmchat RT @DrSanjayPopat: @BrendonStilesMD @VamsiVelcheti Three more large phase 3 trials on #immunotherapy in ES- SCLC are due to report in 2019. My prediction is that this disease will be transformed #LCSM |
| #LCSM Chat @lcsmchat RT @LungRoadAhead: Where there is a will there’s a way. We have to find that way. #lcsm |
 | Alicia C. Staley @stales RT @JFreemanDaily: Amen to this! NSCLC patients need access to genomic testing, but it does no good if we can't access the appropriate meds. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD Again this is a discussion that needs to permeate with PCPs and family medicine docs. Need champions in primary care to spread the gospel. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @IASLC: @JFreemanDaily This is an amazing group and we appreciate each one of you. Thanks for putting aside your time to teach, to learn, and to move progress in #lungcancer forward. #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: @JFreemanDaily This is an amazing group and we appreciate each one of you. Thanks for putting aside your time to teach, to learn, and to move progress in #lungcancer forward. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @tilting Truly, access to expensive new #cancer meds is an issue for national health systems especially. #LCSM |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: Again this is a discussion that needs to permeate with PCPs and family medicine docs. Need champions in primary care to spread the gospel. #LCSM |
| Bob Steele @steele_bob RT @JFreemanDaily: @tilting Truly, access to expensive new #cancer meds is an issue for national health systems especially. #LCSM |
| Denise Cutlip @dennycee More than ever an exciting time to be a pt and advocate #lcsm |
| IASLC @IASLC @JFreemanDaily Should anyone have more questions about #WCLC2018, please contact the IASLC. Don’t forget about #WCLC19 (we’re changing the hashtag) next Sept in Barcelona. #lcsm |
| Janet Freeman-Daily @JFreemanDaily From your mouth to the Powers That Be ... hopeful ES-SCLC will have an effective treatment by the end of 2019. #LCSM |
| IASLC @IASLC RT @DrSanjayPopat: @BrendonStilesMD @VamsiVelcheti Three more large phase 3 trials on #immunotherapy in ES- SCLC are due to report in 2019. My prediction is that this disease will be transformed #LCSM |
| Jill Feldman @jillfeldman4 My thought on #WCLC2018 practice-changing developments - even with the most promising advancements there are challenges, but the important part is knowing the science and applying it in the context of everything else that is part of being human/in a patient's life #LCSM |
| #LCSM Chat @lcsmchat Thank you @JFreemanDaily for moderating this evening, and thanks to @IASLC for #WCLC2018! Wonderful to partner with you tonight. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD Or @DrOz #LCSM |
| Bob Steele @steele_bob RT @JFreemanDaily: From your mouth to the Powers That Be ... hopeful ES-SCLC will have an effective treatment by the end of 2019. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @tilting Truly, access to expensive new #cancer meds is an issue for national health systems especially. #LCSM |
| #LCSM Chat @lcsmchat RT @dennycee: More than ever an exciting time to be a pt and advocate #lcsm |
| #LCSM Chat @lcsmchat RT @IASLC: @JFreemanDaily Should anyone have more questions about #WCLC2018, please contact the IASLC. Don’t forget about #WCLC19 (we’re changing the hashtag) next Sept in Barcelona. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: From your mouth to the Powers That Be ... hopeful ES-SCLC will have an effective treatment by the end of 2019. #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @lcsmchat: Thank you @JFreemanDaily for moderating this evening, and thanks to @IASLC for #WCLC2018! Wonderful to partner with you tonight. #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: My thought on #WCLC2018 practice-changing developments - even with the most promising advancements there are challenges, but the important part is knowing the science and applying it in the context of everything else that is part of being human/in a patient's life #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @jillfeldman4: My thought on #WCLC2018 practice-changing developments - even with the most promising advancements there are challenges, but the important part is knowing the science and applying it in the context of everything else that is part of being human/in a patient's life #LCSM |
| IASLC @IASLC #LCSM Chat Tweet 11: Scott Antonia kicks things off presenting on second primary endpoint of OS for PACIFIC trial. #WCLC2018 #LocoregionalDisease https://t.co/XGHbJvQtu2 |
| Dr. David Tom Cooke @DavidCookeMD RT @IASLC: @JFreemanDaily Should anyone have more questions about #WCLC2018, please contact the IASLC. Don’t forget about #WCLC19 (we’re changing the hashtag) next Sept in Barcelona. #lcsm |
| IASLC @IASLC Grateful for the #lcsm community. |
| Bob Steele @steele_bob Great group chat session! Look forward to seeing you in 2 weeks. #lcsm |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 11: #LCSM Chat Tweet 11: Scott Antonia kicks things off presenting on second primary endpoint of OS for PACIFIC trial. #WCLC2018 #LocoregionalDisease https://t.co/XGHbJvQtu2 |
| Janet Freeman-Daily @JFreemanDaily Thanks everyone for joining our discussion of #WCLC2018 key presentations! Be sure to join our next #LCSM Chat in 2 weeks. |
| Dr. David Tom Cooke @DavidCookeMD RT @jillfeldman4: 'Oncology is a Team Sport' - Another favorite slide from #WCLC2018 #LCSM https://t.co/TuzqQeVc29 |
| Janet Freeman-Daily @JFreemanDaily RT @IASLC: #LCSM Chat Tweet 11: #LCSM Chat Tweet 11: Scott Antonia kicks things off presenting on second primary endpoint of OS for PACIFIC trial. #WCLC2018 #LocoregionalDisease https://t.co/XGHbJvQtu2 |
| Bob Steele @steele_bob RT @jillfeldman4: 'Oncology is a Team Sport' - Another favorite slide from #WCLC2018 #LCSM https://t.co/TuzqQeVc29 |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: My thought on #WCLC2018 practice-changing developments - even with the most promising advancements there are challenges, but the important part is knowing the science and applying it in the context of everything else that is part of being human/in a patient's life #LCSM |
| Bob Steele @steele_bob RT @JFreemanDaily: Thanks everyone for joining our discussion of #WCLC2018 key presentations! Be sure to join our next #LCSM Chat in 2 weeks. |
| IASLC @IASLC #LCSM Chat Tweet 12: @JackWestMD making a strong case for local therapy in oligometastatic NSCLC @IASLC. #WCLC2018 #EarlyStageDisease (Tweet credit: Nat Lester-Coll) https://t.co/hDBYLjWM8f |
| Bob Steele @steele_bob RT @IASLC: #LCSM Chat Tweet 12: #LCSM Chat Tweet 12: @JackWestMD making a strong case for local therapy in oligometastatic NSCLC @IASLC. #WCLC2018 #EarlyStageDisease (Tweet credit: Nat Lester-Coll) https://t.co/hDBYLjWM8f |
| Janet Freeman-Daily @JFreemanDaily RT @IASLC: @JFreemanDaily Should anyone have more questions about #WCLC2018, please contact the IASLC. Don’t forget about #WCLC19 (we’re changing the hashtag) next Sept in Barcelona. #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @VamsiVelcheti: @BrendonStilesMD the big story IMO was SCLC - haven’t had any “real” positive trial in 3 decades #LCSM |
| Sanjay Mukhopadhyay @smlungpathguy RT @TimAllenMDJD: I think so! But #bias :-) #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @BrendonStilesMD: Amazing thing about #wclc2018 was the progress on multiple fronts: Amazing thing about #wclc2018 was the progress on multiple fronts: screening, stage III, small cell, immunotherapy, targeted therapy. Incredible time to be involved in lung cancer. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @IASLC: #LCSM Chat Tweet 12: #LCSM Chat Tweet 12: @JackWestMD making a strong case for local therapy in oligometastatic NSCLC @IASLC. #WCLC2018 #EarlyStageDisease (Tweet credit: Nat Lester-Coll) https://t.co/hDBYLjWM8f |
| Bob Steele @steele_bob RT @VamsiVelcheti: @BrendonStilesMD the big story IMO was SCLC - haven’t had any “real” positive trial in 3 decades #LCSM |
| Sanjay Mukhopadhyay @smlungpathguy RT @BrendonStilesMD: Lots happening in the ALK world. One great drug after another. Biopsied a 47 yo never smoker with apparent stage IV disease today and HOPING she has an ALK rearrangement. Mucinous features. #lcsm https://t.co/NoN4wZsyQN |
| Sanjay Mukhopadhyay @smlungpathguy RT @JackWestMD: @LeciaSequist @VamsiVelcheti @BrendonStilesMD @StephenVLiu Agree. IMpower133 probably isn't pinnacle that will define std of care in SCLC for 10+ years, but it broke an impasse & is likely just first of many trials we'll see come back pos for SCLC in next few yrs, IMO. #LCSM |
| Sanjay Mukhopadhyay @smlungpathguy RT @BrendonStilesMD: And I have to express my love for PACIFIC and for moving IO into earlier stage trials. Could be game changing and should cure more patients. Yes, cure. #lcsm https://t.co/4zAu6koOVX |
| Sanjay Mukhopadhyay @smlungpathguy RT @VamsiVelcheti: Great presentation by @StephenVLiu landmark #Clinicaltrial #LCSM |
 | Tom Varghese Jr. MD, MS, MBA, FACS 🇺🇸 @TomVargheseJr RT @BrendonStilesMD: Amazing thing about #wclc2018 was the progress on multiple fronts: Amazing thing about #wclc2018 was the progress on multiple fronts: screening, stage III, small cell, immunotherapy, targeted therapy. Incredible time to be involved in lung cancer. #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @BrendonStilesMD: Can I talk about NELSON ??? Incredible results which will hopefully help increase screening rates! #lcsm https://t.co/WoB3UmM4oW |
| Sanjay Mukhopadhyay @smlungpathguy RT @IASLC: #LCSM Chat Tweet 4: #LCSM Chat Tweet 4: Keith Kerr presented on IASLC Blueprint project phase 2B evaluating comparability of PD-L1 scores in fine needle aspirate, biopsy or large surgical resection from same tumor; 24 pathologists scored 31 triplet samples. #WCLC2018 #Immunooncology https://t.co/0r9JHkCQx7 |
#LCSM content from Twitter.